ERBB2 and breast cancer: In this study, we used the data obtained from The Cancer Genome Atlas (TCGA) breast cancer dataset and the Gene Expression Omnibus (GEO) database, then built a four resistance-related genes based risk signature and developed a nomogram to predict the survival of patients with ER+ and HER2- breast cancer in stage I-III.